Key result
Finerenone significantly reduced the urine albumin-to-creatinine ratio compared with placebo in patients with chronic kidney disease (MD -0.30; 95% CI -0.50 to -0.11; P<0.05).
Why the study?
The efficacy and safety of finerenone in patients with chronic kidney disease remained unknown.
Does finerenone improve UACR and reduce cardiovascular disorders in patients with chronic kidney disease?
Population
7,048 patients with CKD across four randomized controlled trials
Comparison
Finerenone vs placebo
Design
Systematic review, meta-analysis, and trial sequential analysis of randomized controlled trials
Authors
Loading...
Reduces UACR and CV risk in CKD; confirms antiproteinuric benefit with hyperkalemia monitoring required.
Meta-Analysis (n=7,048)
Does finerenone improve UACR and reduce cardiovascular disorders in patients with chronic kidney disease?
Mean Difference: -0.3 (95% CI -0.5–-0.11)
p-value: p=<0.05
Finerenone provides an antiproteinuric effect and reduces the risk of cardiovascular disorders in patients with CKD, though it increases the risk of hyperkalemia.
Fu et al. (2021) conducted a meta-analysis in Chronic kidney disease (n=7,048). Finerenone vs. Placebo was evaluated on Urine albumin-to-creatinine ratio (UACR) (MD -0.30, 95% CI -0.50, -0.11, p=<0.05). Finerenone significantly reduced the urine albumin-to-creatinine ratio compared with placebo in patients with chronic kidney disease (MD -0.30; 95% CI -0.50 to -0.11; P<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: